Bullous pemphigoid (BP) is the most frequent autoimmune blistering disorder. The immune reaction targets BP180 and BP230 antigens, 2 components of junctional adhesion complexes at the basement membrane zone. Clinical aspect includes multiple tense bullae on urticarial plaques of the skin. Although the nail apparatus may be affected by the immune process, nail changes have been rarely reported during BP. We report a case of a 72-year-old woman diagnosed with BP who subsequently developed a secondary nail loss of the 2 thumbs and the left middle finger. Also, she presented onycholysis of the fourth left finger with the aspect of roller-coaster of the proximal border at dermoscopy. Steroid therapy at high doses was ineffective and the nail atrophy was permanent.

1.
Tomita
M
,
Tanei
R
,
Hamada
Y
,
Fujimura
T
,
Katsuoka
K
.
A case of localized pemphigoid with loss of toenails
.
Dermatology
.
2002
;
204
(
2
):
155
. .
2.
Gualco
F
,
Cozzani
E
,
Parodi
A
.
Bullous pemphigoid with nail loss
.
Int J Dermatol
.
2005
;
44
(
11
):
967
8
. .
3.
Namba
Y
,
Koizumi
H
,
Kumakiri
M
,
Hashimoto
T
,
Muramatsu
T
,
Ohkawara
A
.
Bullous pemphigoid with permanent loss of the nails
.
Acta Derm Venereol
.
1999
;
79
(
6
):
480
1
. .
4.
Barth
JH
,
Wojnarowska
F
,
Millard
PR
,
Dawber
RP
.
Immunofluorescence of the nail bed in pemphigoid
.
Am J Dermatopathol
.
1987
;
9
(
4
):
349
50
. .
5.
Benmously-Mlika
R
,
Hammami-Ghorbel
H
,
Mokhtar
I
.
Onychomadesis during bullous pemphigoid
.
J Am Acad Dermatol
.
2013
;
69
(
6
):
e306
7
. .
6.
Haneke
E
,
Borradori
L
.
Pterygium in bullous pemphigoid: an unusual complication
.
JAAD Case Rep
.
2020
;
6
(
8
):
737
9
. .
7.
Sinclair
RD
,
Wojnarowska
F
,
Leigh
IM
,
Dawber
RP
.
The basement membrane zone of the nail
.
Br J Dermatol
.
1994
;
131
(
4
):
499
505
.
8.
Gopal
V
,
Shenoy
MM
,
Bejai
V
,
Nargis
T
.
Nail changes in autoimmune blistering disorders: a case-control study
.
Indian J Dermatol Venereol Leprol
.
2018
;
84
(
3
):
373
.
9.
Tosti
A
,
André
M
,
Murrell
DF
.
Nail involvement in autoimmune bullous disorders
.
Dermatol Clin
.
2011
;
29
(
3
):
511
xi
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.